Literature DB >> 7484291

Identification and cloning of human P2U purinoceptor present in osteoclastoma, bone, and osteoblasts.

W B Bowler1, M A Birch, J A Gallagher, G Bilbe.   

Abstract

Extracellular ATP acting through purinoceptors may be an important factor in the modulation of bone turnover. In this study we cloned and sequenced the P2U purinoceptor from osteoclastoma, confirming the recently published human sequence. Furthermore, by the reverse transcriptase-linked polymerase chain reaction (RT-PCR) and Southern blotting we demonstrated expression of P2U receptor mRNA in bone, primary cultures of human bone-derived cells, and two osteosarcoma cell lines, Saos2 and Te85. P2U receptor transcripts were identified in alkaline phosphatase-positive human bone-derived cells isolated by flow cytometry providing strong evidence for the expression of the P2U purinoceptor in mature osteoblasts. P2U receptor transcripts were also detected in a purified giant cell population isolated from osteoclastoma, indicating that this receptor is also expressed by osteoclasts. These data suggest that purinergic agonists may play a role in the regulation of bone metabolism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7484291     DOI: 10.1002/jbmr.5650100720

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  16 in total

Review 1.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 2.  Purinergic signalling in the musculoskeletal system.

Authors:  Geoffrey Burnstock; Timothy R Arnett; Isabel R Orriss
Journal:  Purinergic Signal       Date:  2013-08-14       Impact factor: 3.765

3.  Regulation of epidermal homeostasis through P2Y2 receptors.

Authors:  C J Dixon; W B Bowler; A Littlewood-Evans; J P Dillon; G Bilbe; G R Sharpe; J A Gallagher
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

Review 4.  Uridine nucleotide receptors and their ligands: structural, physiological, and pathophysiological aspects, with special emphasis on the nervous system.

Authors:  E Heilbronn; B H Knoblauch; C E Müller
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

5.  ATP as an osteoclast regulator?

Authors:  T R Arnett; B F King
Journal:  J Physiol       Date:  1997-09-01       Impact factor: 5.182

6.  Towards a revised nomenclature for P1 and P2 receptors.

Authors:  B B Fredholm; M P Abbracchio; G Burnstock; G R Dubyak; T K Harden; K A Jacobson; U Schwabe; M Williams
Journal:  Trends Pharmacol Sci       Date:  1997-03       Impact factor: 14.819

7.  Extracellular nucleotides activate non-selective cation and Ca(2+)-dependent K+ channels in rat osteoclasts.

Authors:  A F Weidema; J Barbera; S J Dixon; S M Sims
Journal:  J Physiol       Date:  1997-09-01       Impact factor: 5.182

8.  Purinergic signaling is required for fluid shear stress-induced NF-κB translocation in osteoblasts.

Authors:  Damian C Genetos; Norman J Karin; Derik J Geist; Henry J Donahue; Randall L Duncan
Journal:  Exp Cell Res       Date:  2011-01-13       Impact factor: 3.905

Review 9.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

10.  ATP is a potent stimulator of the activation and formation of rodent osteoclasts.

Authors:  M S Morrison; L Turin; B F King; G Burnstock; T R Arnett
Journal:  J Physiol       Date:  1998-09-01       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.